Mammalian target of rapamycin (mTOR) inhibitors could be associated with acute nephrotoxicity, according to French researchers. The team describes 4 cancer patients who developed severe acute kidney ...
Industry feedback confirms Rakovina’s approach targeting PTEN-deficient tumours with brain-penetrant ATR/mTOR inhibitors ...
As people age, their immune systems deteriorate. This makes them more susceptible to infections and can mean that vaccines are less effective. New research carried out by Dr. Loren Kell at NDORMS ...
Torqur AG, subsidiary of Swiss Rockets incubator and a clinical-stage company advancing targeted therapies in oncodermatology and oncology, announced the results of the full Phase 2 proof-of-concept ...
Circulating kidney injury molecule-1 (KIM-1) in association with kidney injury biomarkers and outcomes in metastatic renal cell carcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO ...
EHE treatment is highly individualized, involving surgery, ablation, chemotherapy, and mTOR inhibitors, depending on patient-specific factors. Next-generation sequencing helps identify genetic ...
Researchers at Zhejiang University and Zhongshan Institute for Drug Discovery have discovered phosphatidylinositol 3-kinase δ (PI3Kδ) and mammalian target of rapamycin (mTOR; FRAP1) dual inhibitors ...
Groundbreaking studies in mice have sparked a frenzy among longevity enthusiasts—but human trials are still in their infancy. Rapamycin (red) inhibits a protein complex called mTORC1 (mammalian target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results